Philipp Y. Maximov • Russell E. McDaniel •
V. Craig Jordan
2013
I joined the Clinical Research Department of ICI Americas (ICI) in Wilmington, Delaware, in 1973, after competing in the World Championships for Rowing in Moscow, Russia, as a member of the first US women’s rowing team. I mention this competition because as I was part of a team who was pioneering the international competition of women’s crew, I was among the team at ICI who was pioneering the support and development of “targeted therapies,” the first being tamoxifen. The operative word here is team. Having previously worked at the National Cancer Institute supporting the Breast Cancer Task Force, I was considered the most qualified individual at the time in the newly formed ICI to plan and organize the clinical investigation of the antiestrogen ICI46,474 in the United States! I remember asking my director how long it takes to have a drug approved.